Breaking News Instant updates and real-time market news.

ADVM

Adverum Biotechnologies

$5.29

0.11 (2.12%)

18:23
10/13/19
10/13
18:23
10/13/19
18:23

Adverum Biotechnologies reports additional data from Phase 1 trial of ADVM-022

Adverum Biotechnologies announced additional clinical data for the first cohort of patients in the ongoing OPTIC phase 1 clinical trial of ADVM-022, the company's intravitreal injection gene therapy, in treatment-experienced patients with wet age-related macular degeneration. Adverum also announced enrollment plans for the third and fourth cohorts in the ongoing OPTIC trial. The third cohort has been initiated and patients will be treated with ADVM-022 at a dose of 2 x 10^11 vg/eye, the same dose used in the second cohort. Subsequently, patients in the fourth cohort will be treated with ADVM-022 at a dose of 6x10^11 vg/eye, the same dose used in the first cohort. Since inflammation has generally been mild and responsive to steroid eye drops, patients in the third and fourth cohorts will receive prophylactic steroid eye drops instead of prophylactic oral steroids. Previously, on September 12, 2019, Adverum presented data from the first cohort in the ongoing OPTIC trial at a pre-specified 24-week time point. The additional data for this cohort includes key outcomes with a median follow-up of 34 weeks. In treatment-experienced patients previously requiring frequent anti-VEGF injections to maintain vision, the data continue to demonstrate that the single ADVM-022 injection in this cohort was sufficient to maintain vision, with zero rescue injections required for any of the six patients. Aaron Osborne, MBBS, chief medical officer of Adverum, added, "The clinical profile of ADVM-022 demonstrates this gene therapy's potential to be a significant advance for patients with wet AMD. It is very encouraging that there continues to be zero rescue injections in this cohort of treatment-experienced patients with more than 6 months follow-up on all patients. We are expanding the development of ADVM-022 and are excited to share that enrollment is now open for the third cohort in OPTIC. We look forward to being able to deliver this novel intravitreal gene therapy candidate as soon as possible to patients with wet AMD and diabetic retinopathy, our second indication for ADVM-022. We are grateful for all of the investigators, patients, and caregivers who continue to participate in the OPTIC trial." Adverum plans to begin dosing patients in the third cohort of the OPTIC trial in the fourth quarter of 2019 and plans to begin enrollment in the fourth cohort in the first quarter of 2020. Adverum plans to present 52-week data from the first cohort of patients in the OPTIC trial as well as 24-week data from the second cohort of patients in the first half of 2020. Adverum plans to submit an investigational new drug application for the treatment of ADVM-022 in diabetic retinopathy in the first half of 2020. Adverum expects to be able to occupy its new corporate headquarters in Redwood City, CA, by the end of this year, allowing for the expansion of in-house process development capabilities to the 1000-liter production scale.

ADVM Adverum Biotechnologies
$5.29

0.11 (2.12%)

08/14/19
PIPR
08/14/19
NO CHANGE
Target $14
PIPR
Overweight
Piper confident in upcoming Adverum data after management meetings
Piper Jaffray analyst Tyler Van Buren reiterates an Overweight rating on Adverum Biotechnologies with a $14 price target following meetings with management. The analyst expects to see preliminary 24-week results from the "all-important" Phase I Optic study of ADVM-022 on September 12. The results could provide proof of concept for the first intravitreal approach for the eye, "which would be monumental," Van Buren tells investors in a research note. He continues to have a "high level of confidence" in the data following his meetings with management.
08/20/19
LEER
08/20/19
UPGRADE
Target $37
LEER
Market Perform
Regenxbio upgraded to Market Perform on valuation at SVB Leerink
As previously reported, SVB Leerink analyst Mani Foroohar upgraded Regenxbio (RGNX) to Market Perform from Underperform, with a $37 price target, despite long-term headwinds. The analyst believes the current valuation balances the challenges of the company's partnership strategy and early-stage gene therapy pipeline with attractive anticipated royalty streams from Zolgensma and the competitive risk from Adverum Biotechnologies (ADVM) in wet AMD well-appreciated by investors. Nonetheless, Foroohar continues to have reservations about the long-term outlook for the company - intellectual property from the NAV platform has a finite lifetime, which self-limits royalty streams and exposes the company to litigation risk. As core patents approach expiry, the rate of new partnerships should continue to decrease, he adds.
09/13/19
RHCO
09/13/19
NO CHANGE
Target $8
RHCO
Hold
Adverum Biotechnologies price target lowered to $8 from $12 at SunTrust
SunTrust analyst Joon Lee lowered his price target on Adverum Biotechnologies to $8 and kept his Hold rating, saying his discussion with a Key Opinion Leader about the company's presentation reflected concerns about its "unconventional" treatment criteria with "zero rescue injections." The analyst adds that the expert noted 100% of the subjects experiencing some form of inflammation, as reported at The Retina Society meeting, which likely led to reduced dosing in the cohort2 of the trial.
09/17/19
CANT
09/17/19
NO CHANGE
Target $8
CANT
Neutral
Adverum Biotechnologies price target to $8 from $3 at Cantor Fitzgerald
Cantor Fitzgerald analyst Alethia Young raised her price target for Adverum Biotechnologies to $8 from $3 after taking over coverage of the name. The analyst, who keeps a Neutral rating on the shares, thinks ADVM-022 showed activity in the first six patients, but is "bit more cautious" on the safety profile, particularly around inflammation. She expects investor concerns and confusion about the dataset to linger until pending further data.

TODAY'S FREE FLY STORIES

01:55
11/13/19
11/13
01:55
11/13/19
01:55
General news
Asian Market Update: »

Asian Market Update:…

01:55
11/13/19
11/13
01:55
11/13/19
01:55
General news
U.S. CPI preview: analysts're forecasting a »

U.S. CPI preview:…

01:30
11/13/19
11/13
01:30
11/13/19
01:30
General news
Fed's Kashkari now a little more optimistic on the U.S. economy »

Fed's Kashkari now a…

WSM

Williams-Sonoma

$70.48

-0.88 (-1.23%)

21:33
11/12/19
11/12
21:33
11/12/19
21:33
Initiation
Williams-Sonoma initiated at Barclays »

Williams-Sonoma initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

W

Wayfair

$84.57

1.28 (1.54%)

21:31
11/12/19
11/12
21:31
11/12/19
21:31
Initiation
Wayfair initiated at Barclays »

Wayfair initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Dec

VFC

VF Corp.

$84.69

-1.7 (-1.97%)

21:28
11/12/19
11/12
21:28
11/12/19
21:28
Initiation
VF Corp. initiated at Barclays »

VF Corp. initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

URBN

Urban Outfitters

$30.85

0.295 (0.97%)

21:25
11/12/19
11/12
21:25
11/12/19
21:25
Initiation
Urban Outfitters initiated at Barclays »

Urban Outfitters…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

UAA

Under Armour

$17.29

-0.295 (-1.68%)

21:23
11/12/19
11/12
21:23
11/12/19
21:23
Initiation
Under Armour initiated at Barclays »

Under Armour initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ULTA

Ulta Beauty

$244.06

2.19 (0.91%)

21:19
11/12/19
11/12
21:19
11/12/19
21:19
Initiation
Ulta Beauty initiated at Barclays »

Ulta Beauty initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

TJX

TJX

$58.40

-0.14 (-0.24%)

21:15
11/12/19
11/12
21:15
11/12/19
21:15
Initiation
TJX initiated at Barclays »

TJX initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

TPR

Tapestry

$26.38

-0.295 (-1.11%)

21:12
11/12/19
11/12
21:12
11/12/19
21:12
Initiation
Tapestry initiated at Barclays »

Tapestry initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

AFL

Aflac

$53.97

-0.04 (-0.07%)

21:02
11/12/19
11/12
21:02
11/12/19
21:02
Hot Stocks
Aflac names Frederick Crawford new COO »

Aflac announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ROST

Ross Stores

$110.97

-1.16 (-1.03%)

21:00
11/12/19
11/12
21:00
11/12/19
21:00
Initiation
Ross Stores initiated at Barclays »

Ross Stores initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

RL

Ralph Lauren

$111.44

-2.58 (-2.26%)

20:57
11/12/19
11/12
20:57
11/12/19
20:57
Initiation
Ralph Lauren initiated at Barclays »

Ralph Lauren initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RH

RH

$174.48

-0.18 (-0.10%)

20:56
11/12/19
11/12
20:56
11/12/19
20:56
Initiation
RH initiated at Barclays »

RH initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PVH

PVH Corp.

$96.91

0.14 (0.14%)

20:53
11/12/19
11/12
20:53
11/12/19
20:53
Initiation
PVH Corp. initiated at Barclays »

PVH Corp. initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Nov

JWN

Nordstrom

$36.90

-0.52 (-1.39%)

20:51
11/12/19
11/12
20:51
11/12/19
20:51
Initiation
Nordstrom initiated at Barclays »

Nordstrom initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

NKE

Nike

$89.51

-0.52 (-0.58%)

20:46
11/12/19
11/12
20:46
11/12/19
20:46
Initiation
Nike initiated at Barclays »

Nike initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EYE

National Vision

$27.03

0.24 (0.90%)

20:43
11/12/19
11/12
20:43
11/12/19
20:43
Initiation
National Vision initiated at Barclays »

National Vision initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LB

L Brands

$17.53

0.02 (0.11%)

20:40
11/12/19
11/12
20:40
11/12/19
20:40
Initiation
L Brands initiated at Barclays »

L Brands initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

BABA

Alibaba

$186.97

0.26 (0.14%)

20:25
11/12/19
11/12
20:25
11/12/19
20:25
Periodicals
Alibaba gets approval to sell shares in Hong Kong, SCMP reports »

Alibaba has received…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

ENR

Energizer

$42.01

-1.1 (-2.55%)

, SPB

Spectrum Brands

$51.19

-0.76 (-1.46%)

20:25
11/12/19
11/12
20:25
11/12/19
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

ENR

Energizer

$42.01

-1.1 (-2.55%)

SPB

Spectrum Brands

$51.19

-0.76 (-1.46%)

SSYS

Stratasys

$20.74

0.04 (0.19%)

FVRR

Fiverr

$21.56

-0.47 (-2.13%)

MTOR

Meritor

$23.44

-0.25 (-1.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

  • 13

    Nov

  • 13

    Nov

  • 13

    Nov

  • 13

    Nov

  • 21

    Nov

  • 09

    Dec

  • 12

    Dec

DDOG

Datadog

$34.40

0.89 (2.66%)

20:02
11/12/19
11/12
20:02
11/12/19
20:02
Hot Stocks
Datadog establishes Japanese subsidiary »

Datadog announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

  • 19

    Nov

NKE

Nike

$89.51

-0.52 (-0.58%)

, AMZN

Amazon.com

$1,778.33

6.63 (0.37%)

19:40
11/12/19
11/12
19:40
11/12/19
19:40
Periodicals
Nike says to end retail pilot project w/ Amazon.com but continue AWS partnership 

Report from Bloomberg.

NKE

Nike

$89.51

-0.52 (-0.58%)

AMZN

Amazon.com

$1,778.33

6.63 (0.37%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

  • 14

    Nov

  • 15

    Nov

  • 19

    Nov

  • 20

    Nov

HPE

HP Enterprise

$17.34

-0.11 (-0.63%)

, FJTSY

Fujitsu

$0.00

(0.00%)

19:34
11/12/19
11/12
19:34
11/12/19
19:34
Hot Stocks
HP Enterprise's Cray to partner with Fujitsu on 'supercomputer' technology »

Cray, a Hewlett Packard…

HPE

HP Enterprise

$17.34

-0.11 (-0.63%)

FJTSY

Fujitsu

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Nov

  • 09

    Dec

  • 09

    Dec

  • 10

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.